MA23998A1 - Procede pour la preparation du d-tartrate de (-) cis-6 (s) -phenyl -5 (r) -[4-(2-pyrrolidine-1-ylethoxy)- phenyl] -5,6,7,8-tetrahydronaphtalene -2-01 - Google Patents

Procede pour la preparation du d-tartrate de (-) cis-6 (s) -phenyl -5 (r) -[4-(2-pyrrolidine-1-ylethoxy)- phenyl] -5,6,7,8-tetrahydronaphtalene -2-01

Info

Publication number
MA23998A1
MA23998A1 MA24381A MA24381A MA23998A1 MA 23998 A1 MA23998 A1 MA 23998A1 MA 24381 A MA24381 A MA 24381A MA 24381 A MA24381 A MA 24381A MA 23998 A1 MA23998 A1 MA 23998A1
Authority
MA
Morocco
Prior art keywords
phenyl
tetrahydronaphtalene
ylethoxy
pyrrolidine
tartrate
Prior art date
Application number
MA24381A
Other languages
English (en)
Inventor
K Chiu Charles
Meltz Morgan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA23998A1 publication Critical patent/MA23998A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
MA24381A 1995-11-02 1996-10-30 Procede pour la preparation du d-tartrate de (-) cis-6 (s) -phenyl -5 (r) -[4-(2-pyrrolidine-1-ylethoxy)- phenyl] -5,6,7,8-tetrahydronaphtalene -2-01 MA23998A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US612595P 1995-11-02 1995-11-02

Publications (1)

Publication Number Publication Date
MA23998A1 true MA23998A1 (fr) 1997-07-01

Family

ID=21719433

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24381A MA23998A1 (fr) 1995-11-02 1996-10-30 Procede pour la preparation du d-tartrate de (-) cis-6 (s) -phenyl -5 (r) -[4-(2-pyrrolidine-1-ylethoxy)- phenyl] -5,6,7,8-tetrahydronaphtalene -2-01

Country Status (43)

Country Link
US (1) US5948809A (fr)
EP (1) EP0876359B1 (fr)
JP (1) JP3088020B2 (fr)
KR (1) KR19990067280A (fr)
CN (1) CN1067065C (fr)
AP (1) AP713A (fr)
AR (1) AR004078A1 (fr)
AT (1) ATE248827T1 (fr)
AU (1) AU708841B2 (fr)
BG (1) BG63943B1 (fr)
BR (1) BR9611436A (fr)
CA (1) CA2236673C (fr)
CO (1) CO4770967A1 (fr)
CZ (1) CZ287341B6 (fr)
DE (1) DE69629837T2 (fr)
DK (1) DK0876359T3 (fr)
DZ (1) DZ2114A1 (fr)
EG (1) EG21095A (fr)
ES (1) ES2203713T3 (fr)
GT (1) GT199600085A (fr)
HR (1) HRP960503B1 (fr)
HU (1) HU227521B1 (fr)
IL (1) IL124027A (fr)
IS (1) IS1855B (fr)
MA (1) MA23998A1 (fr)
NO (1) NO310358B1 (fr)
NZ (1) NZ318498A (fr)
OA (1) OA11009A (fr)
PE (1) PE17698A1 (fr)
PL (1) PL188633B1 (fr)
PT (1) PT876359E (fr)
RO (1) RO119829B1 (fr)
RU (1) RU2162465C2 (fr)
SI (1) SI0876359T1 (fr)
SK (1) SK282172B6 (fr)
TN (1) TNSN96134A1 (fr)
TR (1) TR199800783T2 (fr)
TW (2) TW581766B (fr)
UA (1) UA51676C2 (fr)
UY (1) UY24362A1 (fr)
WO (1) WO1997016434A1 (fr)
YU (1) YU49123B (fr)
ZA (1) ZA969212B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9703109D0 (en) * 1997-02-14 1997-04-02 Smith & Nephew Compositions
PE20000646A1 (es) * 1998-06-16 2000-08-05 Pfizer Prod Inc Terapia de combinacion para la fragilidad musculoesqueletica
CA2335112A1 (fr) * 1998-06-16 1999-12-23 Hua Zhu Ke Combinaisons therapeutiques pour la fragilite musculo-squelettique
EP0966968B1 (fr) * 1998-06-16 2004-05-06 Pfizer Products Inc. Combinaisons thérapeutiques contenant un modulateur sélectif du récepteur oestrogénique et de la prostaglandine E2
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271696A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
HUP0300419A3 (en) 2000-04-07 2005-07-28 Pfizer Prod Inc Estrogen agonist/antagonist metabolites, pharmaceutical compositions containing them and their use
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
ES2274854T3 (es) 2000-05-08 2007-06-01 Pfizer Products Inc. Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
CZ20032959A3 (cs) 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
CN1599606A (zh) * 2001-07-31 2005-03-23 辉瑞产品公司 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法
RU2317104C2 (ru) * 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
HUP0500025A3 (en) * 2002-03-28 2005-10-28 Pfizer Prod Inc Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
EP1765461A1 (fr) * 2004-06-21 2007-03-28 Pharmacia & Upjohn Company LLC Inhibiteurs de pyk2 pour la stimulation de la fonction de l'osteoblaste
BRPI0512245A (pt) * 2004-06-30 2008-02-19 Lilly Co Eli composto, composição farmacêutica, e, uso do composto
EP1899310B1 (fr) 2005-06-22 2010-09-29 Pfizer Products Inc. Procede d'hydrogenation stereoselective la preparation de chlorhydrate de cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphtalene
CZ2007373A3 (cs) * 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
EP2424839A4 (fr) 2009-04-29 2012-10-17 Glenmark Generics Ltd Procédé pour la préparation de tartrate de lasofoxifène
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN103113323B (zh) * 2013-02-05 2015-11-11 南京华威医药科技开发有限公司 酒石酸拉索昔芬中间体的制备方法
RU2019114079A (ru) 2016-10-11 2020-11-13 Дьюк Юниверсити Лечение er+ рака молочной железы лазофоксифеном
WO2019199891A1 (fr) 2018-04-10 2019-10-17 Duke University Traitement du cancer du sein avec du lasofoxifène
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234090A (en) * 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
US3522319A (en) * 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Also Published As

Publication number Publication date
IL124027A (en) 2001-10-31
DE69629837T2 (de) 2004-05-06
BR9611436A (pt) 1999-03-23
BG102474A (en) 1999-06-30
CN1067065C (zh) 2001-06-13
TR199800783T2 (xx) 1998-08-21
JPH11502866A (ja) 1999-03-09
TW518327B (en) 2003-01-21
EP0876359A1 (fr) 1998-11-11
AU708841B2 (en) 1999-08-12
DZ2114A1 (fr) 2002-07-22
HU227521B1 (en) 2011-07-28
ATE248827T1 (de) 2003-09-15
UA51676C2 (uk) 2002-12-16
DK0876359T3 (da) 2003-11-24
JP3088020B2 (ja) 2000-09-18
PE17698A1 (es) 1998-04-18
CZ132098A3 (cs) 1999-03-17
PL326498A1 (en) 1998-09-28
NZ318498A (en) 1999-06-29
NO310358B1 (no) 2001-06-25
CZ287341B6 (en) 2000-10-11
SK54298A3 (en) 1999-07-12
CA2236673C (fr) 2002-03-19
EP0876359B1 (fr) 2003-09-03
AU6998496A (en) 1997-05-22
TW581766B (en) 2004-04-01
GT199600085A (es) 1998-04-04
SI0876359T1 (en) 2003-12-31
HUP9900087A3 (en) 1999-11-29
UY24362A1 (es) 1997-04-24
KR19990067280A (ko) 1999-08-16
HRP960503A2 (en) 1998-04-30
US5948809A (en) 1999-09-07
DE69629837D1 (de) 2003-10-09
YU57896A (sh) 1998-12-23
AP713A (en) 1998-12-28
AR004078A1 (es) 1998-09-30
YU49123B (sh) 2004-03-12
ZA969212B (en) 1998-05-04
AP9600880A0 (en) 1997-01-31
HRP960503B1 (en) 2001-12-31
RU2162465C2 (ru) 2001-01-27
IS4718A (is) 1998-04-16
CA2236673A1 (fr) 1997-05-09
HUP9900087A2 (hu) 1999-05-28
RO119829B1 (ro) 2005-04-29
NO981962L (no) 1998-04-30
ES2203713T3 (es) 2004-04-16
WO1997016434A1 (fr) 1997-05-09
IS1855B (is) 2003-02-21
CN1201458A (zh) 1998-12-09
BG63943B1 (bg) 2003-07-31
CO4770967A1 (es) 1999-04-30
PT876359E (pt) 2003-12-31
EG21095A (en) 2000-10-31
TNSN96134A1 (fr) 1998-12-31
SK282172B6 (sk) 2001-11-06
OA11009A (en) 2003-03-03
PL188633B1 (pl) 2005-03-31
NO981962D0 (no) 1998-04-30
MX9803544A (es) 1998-09-30

Similar Documents

Publication Publication Date Title
MA23998A1 (fr) Procede pour la preparation du d-tartrate de (-) cis-6 (s) -phenyl -5 (r) -[4-(2-pyrrolidine-1-ylethoxy)- phenyl] -5,6,7,8-tetrahydronaphtalene -2-01
MA24205A1 (fr) Procede pour la preparation du sildenafil
MA23270A1 (fr) Procede pour la preparation de nouveaux composes.
MA23792A1 (fr) Procede pour la preparation de nouveaux composes
MA24011A1 (fr) Procede pour la preparation de nouveaux composes
FR2791580B1 (fr) Procede pour l'enrobage de particules
MA22176A1 (fr) Procede pour l'obtention des compositions antimalariales
MA25223A1 (fr) Procede pour la preparation de 4-carboxy-amino-2-substitue-1,2,3,4 tetrahydroquinoleine
MA23802A1 (fr) Procede pour la preparation de nouveaux composes
FR2740132B1 (fr) Procede pour la preparation de 1,1,1,3,3-pentafluoropropane
MA25984A1 (fr) Procede pour preparation de maleate d'amlodipine.
MA21962A1 (fr) Procede pour la preparation d'inhibiteurs de proteass retrovirales .
MA23858A1 (fr) Un procede pour la preparation de hydrochlorure de lercanidipine
FR2802912B1 (fr) Procede pour preparer un polymere d'aluminosilicate
MA24182A1 (fr) Procede pour la preparation de 2,4-diaminopyrimidines substituees
MA23134A1 (fr) Procede pour la preparation d'aryl-piperidine carbinols .
FR2773558B1 (fr) Procede pour l'obtention de 1-butene
MA24534A1 (fr) Procede pour la production d'irones
MA21984A1 (fr) Procede pour la preparation de derives de quilinone .
FR2733227B1 (fr) Procede pour la preparation de 1,1-difluoroethane
MA21273A1 (fr) Procede pour l'obtention de derives d'hydrazine utiles comme antihypertenseurs;
FR2662161B1 (fr) Procede pour le dedoublement de derives d'acide 3-(phenyl 4-substitue)-glycidique.
FR2729387B1 (fr) Procede pour la fabrication d'hydroxy-alcoxy-benzophenones
FR2643647B1 (fr) Procede microbiologique d'obtention de methylcetones
FR2800376B1 (fr) Procede pour la production d'alkylhalogenosilanes